Skip to content

Therapeutic effect of bronchoscopy on lobar / segmental pneumonia

Therapeutic effect of bronchoscopy on lobar / segmental pneumonia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062358
Enrollment
Unknown
Registered
2022-08-02
Start date
2022-08-08
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Therapeutic effect of bronchoscopy on lobar / segmental pneumonia

Interventions

Routine medical treatment and Bronchoscopy group:None
only routine medical treatment group:None

Sponsors

The First Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
29 Days to 14 Years

Inclusion criteria

Inclusion criteria: 1. Age: >= 29 days - <= 14 years; 2. Course from onset to admission: <= 10 days; 3. Meet the diagnostic criteria of lobar pneumonia: The diagnosis of lobar pneumonia requires symptoms of respiratory tract infection such as fever and/or coughing with uniform consolidation of one or more segments and one or more lobes of the lung indicated by chest radiographic imaging while pulmonary tuberculosis and space occupying lesions should be excluded; 4. Meet the indications of bronchoscopic alveolar lavage and implemented in accordance with the expert consensus of Chinese pediatric flexible bronchoscopy guidelines of 2018 edition.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications to bronchoscopy, such as heart failure, severe arrhythmia, severe pulmonary insufficiency and acute respiratory failure; 2. Patients with other kinds of respiratory diseases, such as hospital acquired pneumonia, foreign body aspiration, pulmonary tuberculosis, bronchial asthma, pulmonary thromboembolism and lung tumor; 3. Patients with other systemic diseases which will affect the diagnosis and treatment process, such as diseases of blood system, rheumatic connective tissue, etc.

Design outcomes

Primary

MeasureTime frame
Imaging improvement rate;

Secondary

MeasureTime frame
Length of stay;Duration of heat;Duration of signs;Hospitalization expenses;WBC before and after treatment;CRP before and after treatment;PCT before and after treatment;NLR before and after treatment;NCRbefore and after treatment;D-D before and after treatment;SF before and after treatment;LDH before and after treatment;

Countries

China

Contacts

Public ContactFanzheng Meng

The First Hospital of Jilin University

fzmeng@jlu.edu.cn+86 15043025556

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026